相关实验视频

Updated: Jun 23, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

低剂量德平加维尼托克拉克斯作为高风险髓状瘤的移植后维护

Katherine Parks¹, Kendall Diebold², Donna Salzman²

¹Department of Internal Medicine University of Alabama at Birmingham Birmingham Alabama USA.

|June 19, 2024

概括

在全源干细胞移植 (allo-SCT) 后,低剂量德西他宾和维尼托克拉克斯 (DEC/VEN) 维护对急性髓性白血病 (AML) 和骨髓质综合征 (MDS) 患者显示出有前途的结果,复发率低.

科学领域:

血液学血液学血液学
在瘤学瘤学.
干细胞移植干细胞移植

背景情况:

复发是急性髓性白血病 (AML) 和骨髓质综合征 (MDS) 的全源干细胞移植 (allo-SCT) 后的主要挑战.
有效的移植后策略对于改善这些患者的治疗结果至关重要.

研究的目的:

评估低剂量西他和维尼托克拉克斯 (DEC/VEN) 作为后SCT的维持疗法的安全性和疗效.
评估DEC/VEN对复发率,移植与宿主疾病 (GVHD) 以及AML和MDS患者的存活率的影响.

主要方法:

对26名患有AML和MDS的老年患者进行了回顾性分析,这些患者接受了DEC/VEN后SCT.
评估急性和慢性GVHD的累积发病率.
评估非复发死亡率,复发发病率和整体存活率.

主要成果:

III-IV级急性GVHD (5%) 和1年中度至重度慢性GVHD (26%) 的累积发病率较低.
一位患者在移植后14个月内复发.
一年非复发死亡率为11%,整体存活率为84%.

结论:

低剂量DEC/VEN似乎是一种安全且潜在有效的维护策略.
这种方法可以显著降低AML和MDS患者移植后复发的风险.

关键词:

德西巴因 (decitabine) 是一种药物.维护化疗是维持化疗的方法.骨髓性白血病是一种白血病.移植后的情况.维尼托克莱克斯 (Venetoclax) 是一个

更多相关视频

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

Expansion and Enrichment of Gamma-Delta γδ T Cells from Apheresed Human Product

Expansion and Enrichment of Gamma-Delta γδ T Cells from Apheresed Human Product

Published on: September 22, 2021

相关概念视频

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...